يعرض 1 - 14 نتائج من 14 نتيجة بحث عن '"компрессия спинного мозга"', وقت الاستعلام: 0.60s تنقيح النتائج
  1. 1
    Academic Journal

    المصدر: Siberian journal of oncology; Том 21, № 2 (2022); 96-108 ; Сибирский онкологический журнал; Том 21, № 2 (2022); 96-108 ; 2312-3168 ; 1814-4861 ; 10.21294/1814-4861-2022-21-2

    وصف الملف: application/pdf

    Relation: https://www.siboncoj.ru/jour/article/view/2095/974; Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2018 году. М., 2019. 250 с.; Ratasvuori M., Wedin R., Keller J., Nottrott M., Zaikova O., Bergh P., Kalen A., Nilsson J., Jonsson H., Laitinen M. Insight opinion to surgically treated metastatic bone disease: Scandinavian Sarcoma Group Skeletal Metastasis Registry report of 1195 operated skeletal metastasis. Surg Oncol. 2013; 22(2): 132–8. doi:10.1016/j.suronc.2013.02.008.; Willeumier J.J., van der Linden Y.M., van de Sande M.A.J., Dijkstra P.D.S. Treatment of pathological fractures of the long bones. EFORT Open Rev. 2017; 1(5): 136–45. doi:10.1302/2058-5241.1.000008.; Biermann J.S., Holt G.E., Lewis V.O., Schwartz H.S., Yaszemski M.J. Metastatic bone disease: diagnosis, evaluation, and treatment. J Bone Joint Surg Am. 2009; 91(6): 1518–30.; Bickels J., Dadia S., Lidar Z. Surgical management of metastatic bone disease. J Bone Joint Surg Am. 2009; 91(6): 1503–16. doi:10.2106/JBJS.H.00175.; Ashford R.U., Pendlebury S., Stalley P.D. Management of metastatic disease of the appendicular skeleton. Curr Orthop 2006; 20: 299–315.; Shibata H., Kato S., Sekine I., Abe K., Araki N., Iguchi H., Izumi T., Inaba Y., Osaka I., Kato S., Kawai A., Kinuya S., Kodaira M., Kobayashi E., Kobayashi T., Sato J., Shinohara N., Takahashi S., Takamatsu Y., Takayama K., Takayama K., Tateishi U., Nagakura H., Hosaka M., Morioka H., Moriya T., Yuasa T., Yurikusa T., Yomiya K., Yoshida M. Diagnosis and treatment of bone metastasis: comprehensive guideline of the Japanese Society of Medical Oncology, Japanese Orthopedic Association, Japanese Urological Association, and Japanese Society for Radiation Oncology. ESMO Open. 2016; 1(2). doi:10.1136/esmoopen-2016-000037.; Ruggieri P., Mavrogenis AF, Casadei R., Errani C., Angelini A., Calabrò T., Pala E., Mercuri M. Protocol of surgical treatment of long bone pathological fractures. Injury. 2010; 41: 1161–7. doi:10.1016/j.injury.2010.09.018.; Szendrői M., Antal1 I., Szendrői A., Lazáry A., Varga P.P. Diagnostic algorithm, prognostic factors and surgical treatment of metastatic cancer diseases of the long bones and spine. EFORT Open Rev. 2017; 2(9): 372–381. doi:10.1302/2058-5241.2.170006.; Mirels H. Metastatic disease in long bones. A proposed scoring system for diagnosing impending pathologic fractures. Clin Orthop Relat Res. 1989; 249: 256–64.; Laitinen M., Ratasvuori M., Pakarinen T.-K. The multi-modal approach to metastatic diseases. European Intructional Lectures. Berlin, Heidelberg: Springer, 2012. 35–44. doi:10.1007/978-3-642-27293-6_4.; Forsberg J.A., Eberhardt J., Boland P.J., Wedin R., Healey J.H. Estimating survival in patients with operable skeletal metastases: an application of a bayesian belief network. PLoS One. 2011; 6(5). doi:10.1371/journal.pone.0019956.; Katagiri H., Okada R., Takagi T., Takahashi M., Murata H., Harada H., Nishimura T., Asakura H., Ogawa H. New prognostic factors and scoring system for patients with skeletal metastasis. Cancer Med. 2014; 3: 1359–67. doi:10.1002/cam4.292.; Westhoff P.G., de Graeff A., Monninkhof E.M., Bollen L., Dijkstra S.P., van der Steen-Banasik E.M., van Vulpen M., Leer J.W., Marijnen C.A., van der Linden Y.M.; Dutch Bone Metastasis Study Group. An easy tool to predict survival in patients receiving radiation therapy for painful bone metastases. Int J Radiat Oncol Biol Phys. 2014; 90(4): 739–47. doi:10.1016/j.ijrobp.2014.07.051.; Janssen S.J., van der Heijden A.S., van Dijke M., Ready J.E., Raskin K.A., Ferrone M.L., Hornicek F.J., Schwab J.H. 2015 Marshall Urist Young Investigator Award: Prognostication in Patients With Long Bone Metastases: Does a Boosting Algorithm Improve Survival Estimates? Clin Orthop Relat Res. 2015; 473(10): 3112–21. doi:10.1007/s11999-015-4446-z.; Bollen L., van der Linden Y.M., Pondaag W., Fiocco M., Pattynama B.P., Marijnen C.A., Nelissen R.G., Peul W.C., Dijkstra P.D. Prognostic factors associated with survival in patients with symptomatic spinal bone metastases: a retrospective cohort study of 1,043 patients. Neuro Oncol. 2014; 16(7): 991–8. doi:10.1093/neuonc/not318.; Toyoda Y., Shinohara N., Harabayashi T., Abe T., Akino T., Sazawa A., Nonomura K. Survival and prognostic classification of patients with metastatic renal cell carcinoma of bone. Eur Urol. 2007; 52(1): 163–8. doi:10.1016/j.eururo.2006.10.060.; Nathan S.S., Healey J.H., Mellano D., Hoang B., Lewis I., Morris C.D., Athanasian E.A., Boland P.J. Survival in patients operated on for pathologic fracture: implications for end-of-life orthopedic care. J Clin Oncol. 2005; 23(25): 6072–82. doi:10.1200/JCO.2005.08.104.; Kirkinis M.N., Lyne C.J., Wilson M.D., Choong P.F. Metastatic bone disease: A review of survival, prognostic factors and outcomes following surgical treatment of the appendicular skeleton. Eur J Surg Oncol. 2016; 42(12): 1787–97. doi:10.1016/j.ejso.2016.03.036.; Hansen B.H., Keller J., Laitinen M., Berg P., Skjeldal S., Trovik C., Nilsson J., Walloe A., Kalén A., Wedin R. The Scandinavian Sarcoma Group Skeletal Metastasis Register. Survival after surgery for bone metastases in the pelvis and extremities. Acta Orthop Scand Suppl. 2004; 75(311): 11–5. doi:10.1080/00016470410001708270.; Lin P.P., Mirza A.N., Lewis V.O., Cannon C.P., Tu S.M., Tannir N.M., Yasko A.W. Patient survival after surgery for osseous metastases from renal cell carcinoma. J Bone Joint Surg Am. 2007; 89(8): 1794–801. doi:10.2106/JBJS.F.00603.; Fuhrman S.A., Lasky L.C., Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982; 6(7): 655–63. doi:10.1097/00000478-198210000-00007.; Harries M., Taylor A., Holmberg L., Agbaje O., Garmo H., Kabilan S., Purushotham A. Incidence of bone metastases and survival after a diagnosis of bone metastases in breast cancer patients. Cancer Epidemiol. 2014; 38(4): 427–34. doi:10.1016/j.canep.2014.05.005.; Dürr H.R., Müller P.E., Lenz T., Baur A., Jansson V., Refior H.J. Surgical treatment of bone metastases in patients with breast cancer. Clin Orthop Relat Res. 2002; (396): 191–6.; Ahn S.G., Lee H.M., Cho S.H., Lee S.A., Hwang S.H., Jeong J., Lee H.D. Prognostic factors for patients with bone-only metastasis in breast cancer. Yonsei Med J. 2013; 54(5): 1168–77. doi:10.3349/ymj.2013.54.5.1168.; Weiss R.J., Tullberg E., Forsberg J.A., Bauer H.C., Wedin R. Skeletal metastases in 301 breast cancer patients: patient survival and complications after surgery. Breast. 2014; 23(3): 286–90. doi:10.1016/j.breast.2014.02.012.; Hwang N., Nandra R., Grimer R.J., Carter S.R., Tillman R.M., Abudu A., Jeys L.M. Massive endoprosthetic replacement for bone metastases resulting from renal cell carcinoma: factors influencing patient survival. Eur J Surg Oncol. 2014; 40(4): 429–34. doi:10.1016/j.ejso.2013.08.001.; Oster G., Lamerato L., Glass A.G., Richert-Boe K.E., Lopez A., Chung K., Richhariya A., Dodge T., Wolff G.G., Balakumaran A., Edelsberg J. Natural history of skeletal-related events in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems. Support Care Cancer. 2013; 21(12): 3279–86. doi:10.1007/s00520-013-1887-3.; Sugiura H., Yamada K., Sugiura T., Hida T., Mitsudomi T. Predictors of survival in patients with bone metastasis of lung cancer. Clin Orthop Relat Res. 2008; 466(3): 729–36. doi:10.1007/s11999-007-0051-0.; Weiss R.J., Wedin R. Surgery for skeletal metastases in lung cancer. Acta Orthop. 2011; 82: 96–101. doi:10.3109/17453674.2011.552779.; Harvey N., Ahlmann E.R., Allison D.C., Wang L., Menendez L.R. Endoprostheses last longer than intramedullary devices in proximal femur metastases. Clin Orthop Relat Res. 2012; 470(3): 684–91. doi:10.1007/s11999-011-2038-0.; Mavrogenis A.F., Pala E., Romagnoli C., Romantini M., Calabro T., Ruggieri P. Survival analysis of patients with femoral metastases. J Surg Oncol. 2012; 105(2): 135–41. doi:10.1002/jso.22061.; Wedin R., Hansen B.H., Laitinen M., Trovik C., Zaikova O., Bergh P., Kalén A., Schwarz-Lausten G., Vult von Steyern F., Walloe A., Keller J., Weiss R.J. Complications and survival after surgical treatment of 214 metastatic lesions of the humerus. J Shoulder Elbow Surg. 2012; 21(8): 1049–55. doi:10.1016/j.jse.2011.06.019.; Nakayama R., Horiuchi K., Susa M., Watanabe I., Watanabe K., Tsuji T., Matsumoto M., Toyama Y., Morioka H. Clinical outcome after bone metastasis (BM) surgery in patients with differentiated thyroid carcinoma (DTC): a retrospective study of 40 cases. Jpn J Clin Oncol. 2014; 44(10): 918–25. doi:10.1093/jjco/hyu099.; Liska F., Schmitz P., Harrasser N., Prodinger P., Rechl H., von Eisenhart-Rothe R. [Metastatic disease in long bones: Review of surgical treatment options]. Unfallchirurg 2018. 121, 37–46. doi:10.1007/s00113-016-0282-1.; Wedin R., Bauer H.C.Surgical treatment of skeletal metastatic lesions of the proximal femur: endoprosthesis or reconstruction nail? J Bone Joint Surg Br. 2005; 87(12): 1653–7. doi:10.1302/0301-620X.87B12.16629.; Harrington K.D. The management of acetabular insufficiency secondary to metastatic malignant disease. J Bone Joint Surg Am. 1981 Apr;63(4):653-64. PMID: 6163784.; Tillman R.M., Myers G.J.C., Abudu A.T., Carter S.R., Grimer R.J. The three-pin modified ‘Harrington’ procedure for advanced metastatic destruction of the acetabulum. J Bone Joint Surg [Br]. 2008; 90-B: 84–7. doi:10.1302/0301-620X.90B1.19892.; Miller B.J., Soni E.E., Gibbs C.P., Scarborough M.T. Intramedullary nails for long bone metastases: why do they fail? Orthopedics. 2011; 34(4). doi:10.3928/01477447-20110228-12.; Weiss K.R., Bhumbra R., Biau D.J., Griffin A.M., Deheshi B., Wunder J.S., Ferguson P.C. Fixation of pathological humeral fractures by the cemented plate technique. J Bone Joint Surg Br. 2011; 93(8): 1093–7. doi:10.1302/0301-620X.93B8.26194.; Jacobs W.B., Perrin R.G. Evaluation and treatment of spinal metastases: an overview. Neurosurg Focus. 2001; 11(6). doi:10.3171/foc.2001.11.6.11.; Smith B.D., Smith G.L., Hurria A., Hortobagyi G.N., Buchholz T.A. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol. 2009; 27(17): 2758–65. doi:10.1200/JCO.2008.20.8983.; Fisher C.G., DiPaola C.P., Ryken T.C., Bilsky M.H., Shaffrey C.I., Berven S.H., Harrop J.S., Fehlings M.G., Boriani S., Chou D., Schmidt M.H., Polly D.W., Biagini R., Burch S., Dekutoski M.B., Ganju A., Gerszten P.C., Gokaslan Z.L., Groff M.W., Liebsch N.J., Mendel E., Okuno S.H., Patel S., Rhines L.D., Rose P.S., Sciubba D.M., Sundaresan N., Tomita K., Varga P.P., Vialle L.R., Vrionis F.D., Yamada Y., Fourney D.R. A novel classification system for spinal instability in neoplastic disease: an evidencebased approach and expert consensus from the Spine Oncology Study Group. Spine (Phila Pa 1976). 2010; 35(22): 1221–9. doi:10.1097/BRS.0b013e3181e16ae2.; Campos M., Urrutia J., Zamora T., Román J., Canessa V., Borghero Y., Palma A., Molina M. The Spine Instability Neoplastic Score: an independent reliability and reproducibility analysis. Spine J. 2014; 14(8): 1466–9. doi:10.1016/j.spinee.2013.08.044.; Arana E., Kovacs F.M., Royuela A., Asenjo B., Pérez-Ramírez Ú., Zamora J.; Spanish Back Pain Research Network Task Force for the Improvement of Inter-Disciplinary Management of Spinal Metastasis. Spine Instability Neoplastic Score: agreement across different medical and surgical specialties. Spine J. 2016; 16(5): 591–9. doi:10.1016/j.spinee.2015.10.006.; Laufer I., Rubin D.G., Lis E., Cox B.W., Stubblefield M.D., Yamada Y., Bilsky M.H. The NOMS framework: approach to the treatment of spinal metastatic tumors. Oncologist. 2013; 18(6): 744–51. doi:10.1634/theoncologist.2012-0293.; Ivanishvili Z., Fourney D.R. Incorporating the Spine Instability Neoplastic Score into a treatment strategy for spinal metastasis: LMNOP. Global Spine J. 2014; 4: 129–36. doi:10.1055/s-0034-1375560.; Lam T.C., Uno H., Krishnan M., Lutz S., Groff M., Cheney M., Balboni T. Adverse Outcomes After Palliative Radiation Therapy for Uncomplicated Spine Metastases: Role of Spinal Instability and SingleFraction Radiation Therapy. Int J Radiat Oncol Biol Phys. 2015; 93(2): 373–81. doi:10.1016/j.ijrobp.2015.06.006.; Lee S.H., Tatsui C.E., Ghia A.J., Amini B., Li J., Zavarella S.M., Tannir N.M., Brown P.D., Rhines L.D. Can the spinal instability neoplastic score prior to spinal radiosurgery predict compression fractures following stereotactic spinal radiosurgery for metastatic spinal tumor?: a post hoc analysis of prospective phase II single-institution trials. J Neurooncol. 2016; 126(3): 509–17. doi:10.1007/s11060-015-1990-z.; Bollen L., Wibmer C., Van der Linden Y.M., Pondaag W., Fiocco M., Peul W.C., Marijnen C.A., Nelissen R.G., Leithner A., Dijkstra S.P. Predictive Value of Six Prognostic Scoring Systems for Spinal Bone Metastases: An Analysis Based on 1379 Patients. Spine (Phila Pa 1976). 2016; 41(3): 155–62. doi:10.1097/BRS.0000000000001192.; Choi D., Fox Z., Albert T., Arts M., Balabaud L., Bunger C., Buchowski J.M., Coppes M.H., Depreitere B., Fehlings M.G., Harrop J., Kawahara N., Martin-Benlloch J.A., Massicotte E.M., Mazel C., Oner F.C., Peul W., Quraishi N., Tokuhashi Y., Tomita K., Verlaan J.J., Wang M., Crockard H.A. Prediction of Quality of Life and Survival After Surgery for Symptomatic Spinal Metastases: A Multicenter Cohort Study to Determine Suitability for Surgical Treatment. Neurosurgery. 2015; 77(5): 698–708. doi:10.1227/NEU.0000000000000907.; Verlaan J.J., Choi D., Versteeg A., Albert T., Arts M., Balabaud L., Bunger C., Buchowski J.M., Chung C.K., Coppes M.H., Crockard H.A., Depreitere B., Fehlings M.G., Harrop J., Kawahara N., Kim E.S., Lee C.S., Leung Y., Liu Z., Martin-Benlloch A., Massicotte E.M., Mazel C., Meyer B., Peul W., Quraishi N.A., Tokuhashi Y., Tomita K., Ulbricht C., Wang M., Oner F.C. Characteristics of Patients Who Survived < 3 Months or > 2 Years After Surgery for Spinal Metastases: Can We Avoid Inappropriate Patient Selection? J Clin Oncol. 2016; 34(25): 3054–61. doi:10.1200/JCO.2015.65.1497.; Laufer I., Zuckerman S.L., Bird J.E., Bilsky M.H., Lazáry Á., Quraishi N.A., Fehlings M.G., Sciubba D.M., Shin J.H., Mesfin A., Sahgal A., Fisher C.G. Predicting Neurologic Recovery after Surgery in Patients with Deficits Secondary to MESCC: Systematic Review. Spine (Phila Pa 1976). 2016; 224–30. doi:10.1097/BRS.0000000000001827.; Gerszten P.C., Mendel E., Yamada Y. Radiotherapy and radiosurgery for metastatic spine disease: what are the options, indications, and outcomes? Spine (Phila Pa 1976). 2009; 34(22): 78–92. doi:10.1097/BRS.0b013e3181b8b6f5.; Chang J.H., Shin J.H., Yamada Y.J., Mesfin A., Fehlings M.G., Rhines L.D., Sahgal A. Stereotactic Body Radiotherapy for Spinal Metastases: What are the Risks and How Do We Minimize Them? Spine (Phila Pa 1976). 2016; 238–45. doi:10.1097/BRS.0000000000001823.; Zuckerman S.L., Laufer I., Sahgal A., Yamada Y.J., Schmidt M.H., Chou D., Shin J.H., Kumar N., Sciubba D.M. When Less Is More: The indications for MIS Techniques and Separation Surgery in Metastatic Spine Disease. Spine (Phila Pa 1976). 2016; 246–53. doi:10.1097/BRS.0000000000001824.; Бухаров А.В., Алиев М.Д., Державин В.А., Ядрина А.В. Стратегия персонализированного хирургического лечения онкологических больных с метастазами в костях. Онкология. Журнал им. П.А. Герцена. 2020. 9(3): 61–5. doi:10.17116/onkolog2020903161.; https://www.siboncoj.ru/jour/article/view/2095

  2. 2
    Academic Journal

    المؤلفون: Fazilov, Shukhratulla

    المصدر: Medical science of Uzbekistan; No. 3 (2022): november-december; 04-08 ; Медицинская наука Узбекистана; № 3 (2022): ноябрь-декабрь; 04-08 ; O`zbekiston tibbiyot ilmi; No. 3 (2022): noyabr-dekabr; 04-08 ; 2181-3612

    وصف الملف: application/pdf

  3. 3
    Academic Journal

    المصدر: Siberian journal of oncology; Том 20, № 4 (2021); 57-63 ; Сибирский онкологический журнал; Том 20, № 4 (2021); 57-63 ; 2312-3168 ; 1814-4861 ; 10.21294/1814-4861-2021-20-4

    وصف الملف: application/pdf

    Relation: https://www.siboncoj.ru/jour/article/view/1865/884; Choi D., Bilsky M., Fehlings M., Fisher C., Gokaslan Z. Spine Oncology-Metastatic Spine Tumors. Neurosurgery. 2017 Mar 1; 80(3S): S131–S137. doi:10.1093/neuros/nyw084.; Georgy B.A. Metastatic spinal lesions: state-of-the-art treatment options and future trends. Am J Neuroradiol. 2008 Oct; 29(9): 1605–11. doi:10.3174/ajnr.A1137.; Harel R., Angelov L. Spine metastases: current treatments and future directions. Eur J Cancer. 2010 Oct; 46(15): 2696–707. doi:10.1016/j.ejca.2010.04.025.; Sciubba D.M., Petteys R.J., Dekutoski M.B., Fisher C.G., Fehlings M.G., Ondra S.L., Rhines L.D., Gokaslan Z.L. Diagnosis and management of metastatic spine disease. A review. J Neurosurg Spine. 2010 Jul; 13(1): 94–108. doi:10.3171/2010.3.SPINE09202.; Cole J.S., Patchell R.A. Metastatic epidural spinal cord compression. Lancet Neurol. 2008 May; 7(5): 459–66. doi:10.1016/S1474-4422(08)70089-9.; Wu J., Zheng W., Xiao J.R., Sun X., Liu W.Z., Guo Q. Health-related quality of life in patients with spinal metastases treated with or without spinal surgery: a prospective, longitudinal study. Cancer. 2010 Aug 15; 116(16): 3875–82. doi:10.1002/cncr.25126.; Feiz-Erfan I., Rhines L.D., Weinberg J.S. The role of surgery in the management of metastatic spinal tumors. Semin Oncol. 2008 Apr; 35(2): 108–17. doi:10.1053/j.seminoncol.2007.12.005.; Falicov A., Fisher C.G., Sparkes J., Boyd M.C., Wing P.C., Dvorak M.F. Impact of surgical intervention on quality of life in patients with spinal metastases. Spine (Phila Pa 1976). 2006 Nov 15; 31(24): 2849–56. doi:10.1097/01.brs.0000245838.37817.40.; Yang S.B., Cho W., Chang U.K. Analysis of prognostic factors relating to postoperative survival in spinal metastases. J Korean Neurosurg Soc. 2012 Mar; 51(3): 127–34. doi:10.3340/jkns.2012.51.3.127.; Chen B., Xiao S., Tong X., Xu S., Lin X. Comparison of the Therapeutic Efficacy of Surgery with or without Adjuvant Radiotherapy versus Radiotherapy Alone for Metastatic Spinal Cord Compression: A Meta-Analysis. World Neurosurg. 2015; 83(6): 1066–73. doi:10.1016/j.wneu.2014.12.039.; Kim J.M., Losina E., Bono C.M., Schoenfeld A.J., Collins J.E., Katz J.N., Harris M.B. Clinical outcome of metastatic spinal cord compression treated with surgical excision ± radiation versus radiation therapy alone: a systematic review of literature. Spine (Phila Pa 1976). 2012 Jan 1; 37(1): 78–84. doi:10.1097/BRS.0b013e318223b9b6.; Карпенко В.Ю., Бухаров А.В., Державин В.А. Хирургическое лечение при солитарном поражении позвоночного столба. Онкология. Журнал им. П.А. Герцена. 2017; 6(1): 12–18. doi:10.17116/onkolog20176112-18.; Бухаров А.В., Алиев М.Д., Державин В.А., Ядрина А.В. Стратегия персонализированного хирургического лечения онкологических больных с метастазами в костях. Онкология. Журнал им. П.А. Герцена. 2020; 9(3): 61–65. doi:10.17116/onkolog2020903161.; Liu T., Wang S., Liu H., Meng B., Zhou F., He F., Shi X., Yang H. Detection of vertebral metastases: a meta-analysis comparing MRI, CT, PET, BS and BS with SPECT. J Cancer Res Clin Oncol. 2017 Mar; 143(3): 457–465. doi:10.1007/s00432-016-2288-z.; Tabouret E., Gravis G., Cauvin C., Loundou A., Adetchessi T., Fuentes S. Long-term survivors after surgical management of metastatic spinal cord compression. Eur Spine J. 2015 Jan; 24(1): 209–15. doi:10.1007/s00586-014-3676-1.; Tokuhashi Y., Matsuzaki H., Toriyama S., Kawano H., Ohsaka S. Scoring system for the preoperative evaluation of metastatic spine tumor prognosis. Spine (Phila Pa 1976). 1990 Nov; 15(11): 1110–3. doi:10.1097/00007632-199011010-00005.; Bauer H., Tomita K., Kawahara N., Abdel-Wanis M.E., Murakami H. Surgical strategy for spinal metastases. Spine (Phila Pa 1976). 2002 May 15; 27(10): 1124–6. doi:10.1097/00007632-200205150-00027.; Serlin R.C., Mendoza T.R., Nakamura Y., Edwards K.R., Cleeland C.S. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain. 1995 May; 61(2): 277–284. doi:10.1016/0304-3959(94)00178-H.; Frankel H.L., Hancock D.O., Hyslop G., Melzak J., Michaelis L.S., Ungar G.H., Vernon J.D., Walsh J.J. The value of postural reduction in the initial management of closed injuries of the spine with paraplegia and tetraplegia. I. Paraplegia. 1969 Nov; 7(3): 179–92. doi:10.1038/sc.1969.30.; Chong S., Shin S.H., Yoo H., Lee S.H., Kim K.J., Jahng T.A.,Gwak H.S. Single-stage posterior decompression and stabilization for metastasis of the thoracic spine: prognostic factors for functional outcome and patients’ survival. Spine J. 2012 Dec; 12(12): 1083–92. doi:10.1016/j.spinee.2012.10.015.; Cho D.C., Sung J.K. Palliative surgery for metastatic thoracic and lumbar tumors using posterolateral transpedicular approach with posterior instrumentation. Surg Neurol. 2009 Apr; 71(4): 424–33. doi:10.1016/j.surneu.2008.02.049.; Han X.X., Tao F., Wang G.W., Li L.L., Zhang C., Ren Z.W., Ma Y.L. Effect of combined treatment including surgery and postoperative adjuvant therapy on spinal metastases of Tomita type 7. Clin Neurol Neurosurg. 2019 Jun; 181: 112–118. doi:10.1016/j.clineuro.2019.04.007.; Sailhan F., Prost S., Zairi F., Gille O., Pascal-Mousselard H., Bennis S., Charles Y.P., Blondel B., Fuentes S.; French Spine Society (SFCR). Retrospective multicenter study by the French Spine Society of surgical treatment for spinal metastasis in France. Orthop Traumatol Surg Res. 2018 Sep; 104(5): 589–595. doi:10.1016/j.otsr.2018.06.006.; Miscusi M., Polli F.M., Forcato S., Ricciardi L., Frati A., Cimatti M., De Martino L., Ramieri A., Raco A. Comparison of minimally invasive surgery with standard open surgery for vertebral thoracic metastases causing acute myelopathy in patients with short- or mid-term life expectancy: surgical technique and early clinical results. J Neurosurg Spine. 2015 May; 22(5): 518–25. doi:10.3171/2014.10.SPINE131201.; Schairer W.W., Carrer A., Sing D.C., Chou D., Mummaneni P.V. Hu S.S., Berven S.H., Burch S., Tay B., Deviren V., Ames C. Hospital readmission rates after surgical treatment of primary and metastatic tumors of the spine. Spine (Phila Pa 1976). 2014 Oct 1; 39(21): 1801–8. doi:10.1097/BRS.0000000000000517.; Lau D., Chan A.K., Theologis A.A., Chou D., Mummaneni P.V., Burch S., Berven S., Deviren V., Ames C. Costs and readmission rates for the resection of primary and metastatic spinal tumors: a comparative analysis of 181 patients. J Neurosurg Spine. 2016 Sep; 25(3): 366–78. doi:10.3171/2016.2.SPINE15954.; Sarkiss C.A., Hersh E.H., Ladner T.R., Lee N., Kothari P., Lakomkin N., Caridi J.M. Risk Factors for Thirty-Day Morbidity and Mortality in Extradural Lumbar Spine Tumor Resection. World Neurosurg. 2018 Jun; 114: e1101–e1106. doi:10.1016/j.wneu.2018.03.155.; https://www.siboncoj.ru/jour/article/view/1865

  4. 4
    Academic Journal

    المصدر: Diagnostic radiology and radiotherapy; № 3 (2017); 26-32 ; Лучевая диагностика и терапия; № 3 (2017); 26-32 ; 2079-5343 ; 10.22328/2079-5343-2017-3

    وصف الملف: application/pdf

    Relation: https://radiag.bmoc-spb.ru/jour/article/view/234/218; Перецманас Е.О. Диагностика и хирургическое лечение специфического и неспецифического спондилита: дис …. д-ра мед. наук. М., 2006. http://medical-diss.com/medicin. [Peretsmanas E.O. Diagnostika i hirurgicheskoe lechenie specificheskogo i nespecific- heskogo spondilita: dis …. d-ra med. nauk. Moscow, 2006. http://medical-diss.com/medicin. (In Russ).]; Ульрих Э.В., Мушкин А.Ю. Вертебрология в терминах, цифрах, рисунках: учебник. СПб.: ЭЛБИ-СПб, 2004. [Ulrich Ev., Mushkin Ay. Vertebrologiya v terminah, cifrah, risunkah: uchebnik. St. Petersburg: ELBI-SPb, 2004 (In Russ).]; Dunn R., Zondagh I., Candy S. Spinal tuberculosis: magnetic resonance imaging and neurological impairment. Spine (Phila Pa 1976), 2011, Mar. 15, Vol. 36 (6), рр. 469–473.; Harkey H.L., аl-Mefty O., Marawi I., Peeler D.F., Haines D.E., Alexander L.F. Experimental chronic compressive cervical myelopathy: effects of decompression. J. Neurosurg., 1995, Vol. 83, рр. 336–341.; Jain A.K. Tuberculosis of spine: Research evidence to treatment guidelines. Indian J Orthop., 2016, Vol. 50 (1), рр. 3–9.; Ohshio I., Hatayama A., Kaneda K., Takahara M., Nagashima K. Correlation between histopathologic feartures and magnetic resonance images of spinal cord lesions. Spine (Phila Pa 1976), 1993, Vol. 18 (9), рр. 1140–1149.; https://radiag.bmoc-spb.ru/jour/article/view/234

  5. 5
    Academic Journal

    المصدر: Research and Practical Medicine Journal; Том 3, № 2 (2016); 78-83 ; Research'n Practical Medicine Journal; Том 3, № 2 (2016); 78-83 ; 2410-1893 ; 10.17709/2409-2231-2016-2

    وصف الملف: application/pdf

    Relation: https://www.rpmj.ru/rpmj/article/view/142/143; Злокачественные новообразования в России в 2014 г. (заболеваемость и смертность). Под ред. А.Д. Каприна, В. В. Старинского, Г. В. Петровой. М., 2016. Доступно: http://www. demoscope.ru/weekly/2016/0685/biblio04.php (дата обращения: 25.03.2016).; Алексеев Б. Я., Нюшко К. М. Гормональная терапия больных раком предстательной железы. Онкоурология. 2007; 3: 57–62.; Русаков И. Г., Алексеев Б. Я., Нюшко К. М. Гормональная терапия препаратом Лейпрорелин (Люкрин-депо®) у больных раком предстательной железы. Онкоурология. 2009; 3: 56–60. doi:10.17650/1726–9776–2009–5-3–56–60; Нюшко К. М., Алексеев Б. Я., Калпинский А. С., Каприн А.Д. лютеинизирующего гормона рилизинг-гормона у больных. Онкоурология. 2014; 4: 70–74. doi:10.17650/1726–9776– 2014–10–4-70–74. doi:10.17650/1726–9776–2014–10–4-70–74; Бирюков В. А., Карякин А.О., Горбань Н. А., Минаева Н. Г., Алексеев Б. Я., Нюшко К. М., и др. Результаты российского многоцентрового проспективного наблюдательного исследования по применению доцетаксела (Таксотер) у пациентов с метастатическим кастрационно-резистентным раком предстательной железы. Онкология. Журнал им. П. А. Герцена. 2013; 1 (6): 36–40.; Быстров С. В., Нюшко К. М., Алексеев Б. Я. Таутакс (доцетаксел) в лечении гормонорефрактерного рака предстательной железы. Эффективная фармакотерапия. 2011; 45: 16–21.; Алексеев Б. Я., Нюшко К. М. Возможности применения абиратерона ацетата в гормональной терапии у больных кастрационно-резистентным раком предстательной железы. Онкология. Журнал им. П. А. Герцена. 2012; 1:. 70–72.; Harada M., Iida M., Yamaguchi M., Shida K. Analysis of bone metastasis of prostate adenocarcinoma in 137 autopsy cases. Adv Exp Mad Biol. 1992; 324: 173–182.; Алексеев Б. Я., Каприн А.Д., Нюшко К. М. Роль аналогов соматостатина в лечении больных гормонорефрактерным раком предстательной железы. Онкоурология. 2011; 2: 84–88.; Алексеев Б. Я., Нюшко К. М. Роль аналогов соматостатина в лечении больных кастрационно-рефрактерным раком предстательной железы. Онкология. Журнал им. П. А. Герцена. 2012; 2:.100–102.; Каприн А.Д., Алексеев Б. Я., Нюшко К. М., Калпинский А. С. Современные подходы к лекарственной терапии больных метастатическим кастрационно-рефрактерным раком предстательной железы. Фарматека. 2014; 8 (281): 35–39.; Алексеев Б. Я., Нюшко К. М., Калпинский А. С., Каприн А.Д. Возможности и концепции лекарственной терапии у больных кастрационнорефрактерным раком предстательной железы. Русский медицинский журнал. 2014; 22 (17): 1234–1238.; Алексеев Б. Я., Нюшко К. М., Крашенинников А. А. Роль аналогов соматостатина в лечении больных кастрационно-рефрактерным раком предстательной железы. Эффективная фармакотерапия. 2013; 6: 32–37.; Нюшко К. М., Алексеев Б. Я. Гормональная терапия препаратом диферелин у больных раком предстательной железы. Эффективная фармакотерапия. 2010; 29: 36–40.; Нюшко К.М., Калпинский А.С., Каприн А.Д. Профилактика развития осложнений у больных раком предстательной железы с метастазами в костях. Исследования и практика в медицине. 2015; 2 (3): 76–81. doi:10.17709/2409–2231–2015–2-3–76–81; Reddi A.H., Roodman D., Freeman C., Mohla S. Mechanisms of tumor metastases to the bone: challenges and opportunities. J of Bone and Mineral Research 2003; 18 (2): 190–194.; Russell R. Determinants of structure-function relationships among bisphosphonates. Bone. 2007; 40 (5): S21 S25.; Dunford J., Thompson K., Coxon F. P., Luckman S. P., Hahn F. M., Poulter C.D., et al. Structure-activity relationships for inhibition of farnesyl disphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 2001; 296 (2): 235–242.; Rodan G., Fleisch H. Bisphosphonates: mechanism of actions. J Clin Invest. 1996; 97: 2692–2696.; Lehenkari P., Kellinsalmi M., Näpänkangas J., Ylitalo K. V., Mönkkönen J., Rogers M.J., et al. Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenosine containing metabolite. Mol Pharmacol. 2002; 61 (5): 1255–1262.; Frith J., Monkkonen J., Auriola S., Mönkkönen H., Rogers M. The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis. Arthritis Rheum. 2001; 44 (9): 2201–2210.; Bergstrom J., Bostedor R., Masarachia P., Reszka A., Rodan G. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys. 2000; 373 (1): 231–241.; Li E., Davis L. Zoledronic acid: a new parenteral bisphosphonate. Clin Ther. 2003; 25 (11): 2669–2708.; Green J. Chemical and biological prerequisites for novel bisphosphonate molecules: Results of comparative preclinical studies. Semin Oncol. 2001; 28 (2 Suppl 6): 4–10.; Benford H., McGowan N., Helfrich M., Nuttall M., Rogers M. Visualization of bisphosphonateinduced caspase 3 activity in apoptotic osteoclasts in vitro. Bone. 2001; 28 (5): 465–473.; Boissier S., Ferreras M., Peyruchaud O., Magnetto S., Ebetino F.H., Colombel M., et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res. 2000;60 (11):2949–2954.; George R., Jeba J., Ramkumar G., Chacko A.G., Leng M., Tharyan P. Interventions for the treatment of metastatic extradural spinal cord compression in adults. Cochrane Database Syst Rev 2008; 8 (4): CD006716.; Black D. M., Delmas P.D., Eastell R., Reid I. R., Boonen S., Cauley J. A., et al. HORIZON Pivotal Fracture Trial. Once yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007; 356: 1809–1822.; Куляев Е. А., Графов А. В., Фаламеева О. В., Храпова Ю. В., Садовой М. А. Опыт применения золедроновой кислоты (Резокластин ФС 5 мг/6,25 мл, ЗАО «Ф Синтез», Россия) у пациентов с низкой минеральной плотностью костной ткани. Эффективная фармакотерапия. 2013; 2 (38): 30–33.; https://www.rpmj.ru/rpmj/article/view/142

  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14